SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Unitedhealth Group Inc – ‘10-Q’ for 9/30/10 – ‘XML.R16’

On:  Wednesday, 11/3/10, at 4:08pm ET   ·   For:  9/30/10   ·   Accession #:  1193125-10-246111   ·   File #:  1-10864

Previous ‘10-Q’:  ‘10-Q’ on 8/5/10 for 6/30/10   ·   Next:  ‘10-Q’ on 5/3/11 for 3/31/11   ·   Latest:  ‘10-Q’ on 5/9/24 for 3/31/24   ·   2 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/03/10  Unitedhealth Group Inc            10-Q        9/30/10   83:13M                                    Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    842K 
 2: EX-10.1     Fourth Amendment to Unitedhealth Group Executive    HTML     33K 
                Savings Plan                                                     
 3: EX-10.2     First Amendment to Unitedhealth Group Directors'    HTML     31K 
                Compensation Deferral Plan                                       
 4: EX-12.1     Ratio of Earnings to Fixed Charges                  HTML     35K 
 5: EX-31.1     Certifications Pursuant to Section 302 of the       HTML     40K 
                Sarbanes-Oxley Act of 2002                                       
 6: EX-32.1     Certifications Pursuant to Section 906 of the       HTML     29K 
                Sarbanes-Oxley Act of 2002                                       
60: XML         IDEA XML File -- Definitions and References          XML    204K 
73: XML         IDEA XML File -- Filing Summary                      XML    296K 
68: XML.R1      Document and Entity Information                      XML    137K 
69: XML.R2      Condensed Consolidated Balance Sheets                XML    355K 
40: XML.R3      Condensed Consolidated Balance Sheets                XML    117K 
                (Parenthetical)                                                  
46: XML.R4      Condensed Consolidated Statements of Operations      XML    352K 
58: XML.R5      Condensed Consolidated Statements of Changes in      XML    470K 
                Shareholders' Equity                                             
56: XML.R6      Condensed Consolidated Statements of Changes in      XML     92K 
                Shareholders' Equity (Parenthetical)                             
79: XML.R7      Condensed Consolidated Statements of Cash Flows      XML    362K 
23: XML.R8      Basis of Presentation, Use of Estimates and          XML     51K 
                Significant Accounting Policies                                  
55: XML.R9      Investments                                          XML    411K 
19: XML.R10     Fair Value                                           XML    190K 
18: XML.R11     Medicare Part D Pharmacy Benefits Contract           XML     56K 
39: XML.R12     Goodwill and Other Intangible Assets                 XML     65K 
63: XML.R13     Medical Costs and Medical Costs Payable              XML     50K 
41: XML.R14     Commercial Paper and Long-Term Debt                  XML    150K 
43: XML.R15     Income Taxes                                         XML     48K 
51: XML.R16     Shareholders' Equity                                 XML     59K 
83: XML.R17     Share-Based Compensation                             XML     96K 
34: XML.R18     Aarp                                                 XML    123K 
13: XML.R19     Comprehensive Income                                 XML     64K 
45: XML.R20     Segment Financial Information                        XML    220K 
62: XML.R21     Commitments and Contingencies                        XML     62K 
28: XML.R22     Basis of Presentation, Use of Estimates and          XML     58K 
                Significant Accounting Policies (Policy)                         
59: XML.R23     Fair Value (Policy)                                  XML     53K 
44: XML.R24     Commercial Paper and Long-Term Debt (Policy)         XML     56K 
78: XML.R25     Aarp (Policy)                                        XML     50K 
65: XML.R26     Commitment and Contingencies (Policy)                XML     46K 
47: XML.R27     Investments (Tables)                                 XML    433K 
52: XML.R28     Fair Value (Tables)                                  XML    185K 
17: XML.R29     Medicare Part D Pharmacy Benefits Contract           XML     54K 
                (Tables)                                                         
21: XML.R30     Goodwill and Other Intangible Assets (Tables)        XML     62K 
29: XML.R31     Commercial Paper and Long-Term Debt (Tables)         XML    151K 
36: XML.R32     Shareholders' Equity (Tables)                        XML     53K 
50: XML.R33     Share-Based Compensation (Tables)                    XML     98K 
64: XML.R34     Aarp (Tables)                                        XML    123K 
15: XML.R35     Comprehensive Income (Tables)                        XML     61K 
24: XML.R36     Segment Financial Information (Tables)               XML    210K 
70: XML.R37     Investments (Narrative) (Details)                    XML    137K 
77: XML.R38     Investments (Short-term and Long-term Investments)   XML    755K 
                (Details)                                                        
48: XML.R39     Investments (Fair Value of the Company's             XML    496K 
                Mortgage-backed Securities by Credit Rating and                  
                Non-U.S. Agency Mortgage-backed Securities by                    
                Origination) (Details)                                           
81: XML.R40     Investments (Amortized Cost and Fair Value of        XML    153K 
                Available-for-sale Debt Securities by Contractual                
                Maturity) (Details)                                              
25: XML.R41     Investments (Amortized Cost and Fair Value of        XML    108K 
                Held-to-maturity Debt Securities by Contractual                  
                Maturity) (Details)                                              
82: XML.R42     Investments (Fair Value of Available-for-sale        XML    524K 
                Investments with Gross Unrealized Losses by                      
                Investment Type and Length of Time That Individual               
                Securities Have Been in a Continuous Unrealized                  
                Loss Position) (Details)                                         
31: XML.R43     Investments (Net Realized Gains, Before Taxes)       XML    140K 
                (Details)                                                        
14: XML.R44     Fair Value (Narrative) (Details)                     XML    116K 
30: XML.R45     Fair Value (Financial Assets and Liabilities,        XML   1.19M 
                Excluding AARP, Measured at Fair Value on a                      
                Recurring basis) (Details)                                       
61: XML.R46     Fair Value (Reconciliation of Assets Measured at     XML    306K 
                Fair Value on a Recurring Basis Using Level 3                    
                Inputs) (Details)                                                
76: XML.R47     Fair Value (Summary of Fair Value and Carrying       XML    123K 
                Value for Certain Financial Instruments for Which                
                it is Practicable to Estimate Fair Value)                        
                (Details)                                                        
42: XML.R48     Medicare Part D Pharmacy Benefits Contract           XML    128K 
                (Condensed Consolidated Balance Sheets Amounts of                
                Medicare Part D Program) (Details)                               
32: XML.R49     Goodwill and Other Intangible Assets (Changes in     XML    214K 
                Carrying Amount of Goodwill by Segment) (Details)                
49: XML.R50     Goodwill and Other Intangible Assets (Narrative)     XML     46K 
                (Details)                                                        
16: XML.R51     Medical Costs and Medical Costs Payable              XML    123K 
                (Narrative) (Details)                                            
53: XML.R52     Commercial Paper and Long-Term Debt (Narrative)      XML    341K 
                (Details)                                                        
33: XML.R53     Commercial Paper and Long-Term Debt (Commercial      XML   1.00M 
                Paper and Long-Term Debt) (Details)                              
22: XML.R54     Commercial Paper and Long-Term Debt (Summary of      XML     60K 
                Location and Fair Value of Fair Value Hedges)                    
                (Details)                                                        
75: XML.R55     Commercial Paper and Long-Term Debt (Effect of       XML    112K 
                Changes in Fair Value of Fair Value Hedges)                      
                (Details)                                                        
72: XML.R56     Income Taxes (Narrative) (Details)                   XML     79K 
38: XML.R57     Shareholders' Equity (Narrative) (Details)           XML     71K 
27: XML.R58     Shareholders' Equity (Schedule of Dividends)         XML    111K 
                (Details)                                                        
66: XML.R59     Share-Based Compensation (Narrative) (Details)       XML    414K 
20: XML.R60     Share-Based Compensation (Stock Option and SAR       XML    176K 
                Activity) (Details)                                              
57: XML.R61     Share-Based Compensation (Share-Based Compensation   XML    227K 
                Principal Fair Value Assumptions) (Details)                      
54: XML.R62     Share-Based Compensation (Restricted Share           XML    110K 
                Activity) (Details)                                              
71: XML.R63     Aarp (AARP Program-related Assets and Liabilities)   XML    180K 
                (Details)                                                        
67: XML.R64     Aarp (AARP Program Financial Assets and              XML   1.52M 
                Liabilities Measured at Fair Value on a Recurring                
                Basis) (Details)                                                 
80: XML.R65     Comprehensive Income (Comprehensive Income)          XML    158K 
                (Details)                                                        
26: XML.R66     Segment Financial Information (Details)              XML    784K 
37: XML.R67     Commitments And Contingencies (Narrative)            XML     65K 
                (Details)                                                        
74: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.02M 
 7: EX-101.INS  XBRL Instance -- unh-20100930                        XML   3.32M 
 9: EX-101.CAL  XBRL Calculations -- unh-20100930_cal                XML    220K 
10: EX-101.DEF  XBRL Definitions -- unh-20100930_def                 XML    488K 
11: EX-101.LAB  XBRL Labels -- unh-20100930_lab                      XML   1.01M 
12: EX-101.PRE  XBRL Presentations -- unh-20100930_pre               XML    852K 
 8: EX-101.SCH  XBRL Schema -- unh-20100930                          XSD    197K 
35: ZIP         XBRL Zipped Folder -- 0001193125-10-246111-xbrl      Zip    171K

‘XML.R16’   —   Shareholders’ Equity

This Financial Report is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<InstanceReport xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
<Version> 2.2.0.7 </Version>
<hasSegments> false </hasSegments>
<ReportName> Shareholders' Equity </ReportName>
<ReportLongName> 10901 - Disclosure - Shareholders' Equity </ReportLongName>
<DisplayLabelColumn> true </DisplayLabelColumn>
<ShowElementNames> false </ShowElementNames>
<RoundingOption/>
<HasEmbeddedReports> false </HasEmbeddedReports>
<Columns>
<Column>
<LabelColumn> false </LabelColumn>
<Id> 1 </Id>
<Labels>
<Label Id="1" Label="9 Months Ended"/>
<Label Id="2" Label="Sep. 30, 2010"/>
</Labels>
<CurrencyCode> USD </CurrencyCode>
<FootnoteIndexer/>
<hasSegments> false </hasSegments>
<hasScenarios> false </hasScenarios>
<Segments/>
<Scenarios/>
<Units>
<Unit>
<UnitID> Unit13 </UnitID>
<UnitType> Divide </UnitType>
<NumeratorMeasure>
<MeasureSchema> http://www.xbrl.org/2003/iso4217 </MeasureSchema>
<MeasureValue> USD </MeasureValue>
<MeasureNamespace> iso4217 </MeasureNamespace>
</NumeratorMeasure>
<DenominatorMeasure>
<MeasureSchema> http://www.xbrl.org/2003/instance </MeasureSchema>
<MeasureValue> shares </MeasureValue>
<MeasureNamespace> xbrli </MeasureNamespace>
</DenominatorMeasure>
<Scale> 0 </Scale>
</Unit>
<Unit>
<UnitID> Unit12 </UnitID>
<UnitType> Standard </UnitType>
<StandardMeasure>
<MeasureSchema> http://www.xbrl.org/2003/iso4217 </MeasureSchema>
<MeasureValue> USD </MeasureValue>
<MeasureNamespace> iso4217 </MeasureNamespace>
</StandardMeasure>
<Scale> 0 </Scale>
</Unit>
<Unit>
<UnitID> Unit14 </UnitID>
<UnitType> Standard </UnitType>
<StandardMeasure>
<MeasureSchema> http://www.xbrl.org/2003/instance </MeasureSchema>
<MeasureValue> pure </MeasureValue>
<MeasureNamespace> xbrli </MeasureNamespace>
</StandardMeasure>
<Scale> 0 </Scale>
</Unit>
<Unit>
<UnitID> Unit1 </UnitID>
<UnitType> Standard </UnitType>
<StandardMeasure>
<MeasureSchema> http://www.xbrl.org/2003/instance </MeasureSchema>
<MeasureValue> shares </MeasureValue>
<MeasureNamespace> xbrli </MeasureNamespace>
</StandardMeasure>
<Scale> 0 </Scale>
</Unit>
</Units>
<CurrencySymbol> $ </CurrencySymbol>
</Column>
</Columns>
<Rows>
<Row>
<Id> 2 </Id>
<Label> Shareholders' Equity </Label>
<Level> 0 </Level>
<ElementName> us-gaap_StockholdersEquityNoteAbstract </ElementName>
<ElementPrefix> us-gaap </ElementPrefix>
<IsBaseElement> true </IsBaseElement>
<BalanceType> na </BalanceType>
<PeriodType> duration </PeriodType>
<ShortDefinition> No definition available. </ShortDefinition>
<IsReportTitle> false </IsReportTitle>
<IsSegmentTitle> false </IsSegmentTitle>
<IsSubReportEnd> false </IsSubReportEnd>
<IsCalendarTitle> false </IsCalendarTitle>
<IsTuple> false </IsTuple>
<IsAbstractGroupTitle> true </IsAbstractGroupTitle>
<IsEquityPrevioslyReportedAsRow> false </IsEquityPrevioslyReportedAsRow>
<IsEquityAdjustmentRow> false </IsEquityAdjustmentRow>
<IsBeginningBalance> false </IsBeginningBalance>
<IsEndingBalance> false </IsEndingBalance>
<IsReverseSign> false </IsReverseSign>
<PreferredLabelRole/>
<IsEPS> false </IsEPS>
<FootnoteIndexer/>
<Cells>
<Cell>
<Id> 1 </Id>
<ShowCurrencySymbol> false </ShowCurrencySymbol>
<IsNumeric> false </IsNumeric>
<IsRatio> false </IsRatio>
<DisplayZeroAsNone> false </DisplayZeroAsNone>
<NumericAmount> 0 </NumericAmount>
<RoundedNumericAmount> 0 </RoundedNumericAmount>
<NonNumbericText/>
<NonNumericTextHeader/>
<FootnoteIndexer/>
<hasSegments> false </hasSegments>
<hasScenarios> false </hasScenarios>
<DisplayDateInUSFormat> false </DisplayDateInUSFormat>
</Cell>
</Cells>
<OriginalInstanceReportColumns/>
<ElementDataType> xbrli:stringItemType </ElementDataType>
<SimpleDataType> string </SimpleDataType>
<ElementDefenition> No definition available. </ElementDefenition>
<IsTotalLabel> false </IsTotalLabel>
</Row>
<Row>
<Id> 3 </Id>
<Label> Shareholders' Equity </Label>
<Level> 1 </Level>
<ElementName> us-gaap_StockholdersEquityNoteDisclosureTextBlock </ElementName>
<ElementPrefix> us-gaap </ElementPrefix>
<IsBaseElement> true </IsBaseElement>
<BalanceType> na </BalanceType>
<PeriodType> duration </PeriodType>
<ShortDefinition> No definition available. </ShortDefinition>
<IsReportTitle> false </IsReportTitle>
<IsSegmentTitle> false </IsSegmentTitle>
<IsSubReportEnd> false </IsSubReportEnd>
<IsCalendarTitle> false </IsCalendarTitle>
<IsTuple> false </IsTuple>
<IsAbstractGroupTitle> false </IsAbstractGroupTitle>
<IsEquityPrevioslyReportedAsRow> false </IsEquityPrevioslyReportedAsRow>
<IsEquityAdjustmentRow> false </IsEquityAdjustmentRow>
<IsBeginningBalance> false </IsBeginningBalance>
<IsEndingBalance> false </IsEndingBalance>
<IsReverseSign> false </IsReverseSign>
<PreferredLabelRole> terselabel </PreferredLabelRole>
<IsEPS> false </IsEPS>
<FootnoteIndexer/>
<Cells>
<Cell>
<Id> 1 </Id>
<ShowCurrencySymbol> false </ShowCurrencySymbol>
<IsNumeric> false </IsNumeric>
<IsRatio> false </IsRatio>
<DisplayZeroAsNone> false </DisplayZeroAsNone>
<NumericAmount> 0 </NumericAmount>
<RoundedNumericAmount> 0 </RoundedNumericAmount>
<NonNumbericText>
<div> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b>9.    Shareholders' Equity </b></font></p> <p style="margin-top: 6px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Share Repurchase Program </i></b></font></p> <p style="margin-top: 6px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">Under its Board of Directors' authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company's capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time at prevailing prices in the open market, subject to certain Board restrictions. In February 2010, the Board renewed and increased the Company's share repurchase program, and authorized the Company to repurchase up to <font class="_mt">120</font> million shares of its common stock. During the nine months ended September 30, 2010, the Company repurchased <font class="_mt">59</font> million shares at an average price of approximately $<font class="_mt">32</font> per share and an aggregate cost of $1.9 billion. As of September 30, 2010, the Company had Board authorization to purchase up to an additional <font class="_mt">65</font> million shares of its common stock. </font></p> <p style="margin-top: 18px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2"><b><i>Dividends </i></b></font></p> <p style="margin-top: 6px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In May 2010, the Company's Board of Directors increased the Company's cash dividend to shareholders and moved the Company to a quarterly dividend payment cycle. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change. Prior to May 2010, the Company's policy had been to pay an annual dividend. </font></p> <p style="margin-top: 12px; margin-bottom: 0px; font-size: 1px;"> </p> <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">The following table provides details of the Company's dividend payments in 2010: </font></p> <p style="margin-top: 0px; margin-bottom: 0px; font-size: 12px;"> </p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="23%"> </td> <td valign="bottom" width="21%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="21%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="21%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom" nowrap="nowrap"> <p style="border-bottom: #000000 1px solid; width: 42pt;"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Record Date</b></font></p></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Payment Date</b></font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Amount per Share</b></font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>Total Amount Paid</b></font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td></tr> <tr><td valign="bottom"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom" colspan="2"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom" colspan="2"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom" colspan="2" align="center"><font style="font-family: Times New Roman;" class="_mt" size="1"><b>(in millions)</b></font></td> <td valign="bottom"><font class="_mt" size="1"> </font></td></tr> <tr bgcolor="#cceeff"><td valign="top" align="center"> <p style="text-indent: -1em; margin-left: 1em;" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">4/6/2010</font></p></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">4/20/2010</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.030</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">34</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td></tr> <tr><td valign="top" align="center"> <p style="text-indent: -1em; margin-left: 1em;" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">6/7/2010</font></p></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">6/21/2010</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.125</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">140</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td></tr> <tr bgcolor="#cceeff"><td valign="top" align="center"> <p style="text-indent: -1em; margin-left: 1em;" align="center"><font style="font-family: Times New Roman;" class="_mt" size="2">9/14/2010</font></p></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">9/28/2010</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">0.125</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td> <td valign="bottom"><font class="_mt" size="1">  </font></td> <td valign="bottom"><font style="font-family: Times New Roman;" class="_mt" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family: Times New Roman;" class="_mt" size="2">139</font></td> <td valign="bottom" nowrap="nowrap"><font style="font-family: Times New Roman;" class="_mt" size="2">  </font></td></tr></table> </div>
</NonNumbericText>
<NonNumericTextHeader> 9.    Shareholders' Equity Share Repurchase Program Under its Board of Directors' authorization, the Company maintains a share repurchase </NonNumericTextHeader>
<FootnoteIndexer/>
<hasSegments> false </hasSegments>
<hasScenarios> false </hasScenarios>
<DisplayDateInUSFormat> false </DisplayDateInUSFormat>
</Cell>
</Cells>
<OriginalInstanceReportColumns/>
<ElementDataType> us-types:textBlockItemType </ElementDataType>
<SimpleDataType> textblock </SimpleDataType>
<ElementDefenition> Disclosures related to accounts comprising shareholders' equity, including other comprehensive income. Includes: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables; effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. </ElementDefenition>
<ElementReferences> Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C, E Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 1 -Section B -Paragraph 7, 11A Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 </ElementReferences>
<IsTotalLabel> false </IsTotalLabel>
</Row>
</Rows>
<Footnotes/>
<NumberOfCols> 1 </NumberOfCols>
<NumberOfRows> 2 </NumberOfRows>
<HasScenarios> false </HasScenarios>
<MonetaryRoundingLevel> UnKnown </MonetaryRoundingLevel>
<SharesRoundingLevel> UnKnown </SharesRoundingLevel>
<PerShareRoundingLevel> UnKnown </PerShareRoundingLevel>
<HasPureData> false </HasPureData>
<SharesShouldBeRounded> true </SharesShouldBeRounded>
</InstanceReport>

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/15/22  UnitedHealth Group Inc.           10-K       12/31/21  113:19M
 3/01/21  UnitedHealth Group Inc.           10-K       12/31/20  107:17M
↑Top
Filing Submission 0001193125-10-246111   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 9, 5:44:37.1pm ET